Herpes indices

or

Why bone hyperplasia

auxological techniques

patients achieving normal

treatment

growth monitored

glucocorticoid

values

good

by

would not

I

infections,

increased

definite depression of

of

et al are to be

or

cles

retrospective

children

The presence of

a


**Monitoring treatment in congenital adrenal hyperplasia**

SIR.—Appan et al are to be congratulated on achieving normal growth in so many of their patients with congenital adrenal hyperplasia.1 I would not wish paediatricians to conclude, however, that the management of this condition merely requires a standard dose of glucocorticoid and mineralocorticoid calculated from surface area to be chosen at birth and growth monitored thereafter until adulthood. The decision to adjust treatment on the basis of an abnormal change in growth velocity or pubertal maturation is inevitably a retrospective one. The author concede that an advanced bone age can rarely be recovered. Why not try to predict such an occurrence before it is too late?

The biochemical indices to monitor control are by no means entirely reliable alone. They are certainly useful to detect problems with treatment compliance, particularly plasma testosterone values which are less influenced by good short term compliance. Appan et al conclude their paper by stating that frequent adjustment of medication is needed during periods of rapid growth in infancy and puberty. Periods of short term monitoring of biochemical indices along the lines recently recommended,2 together with the use of standard auxological techniques in the longer term, is surely a sensible way to achieve this.

1 A Hughes Department of Paediatrics, Level 8, St Thomas’s Hospital, Hills Road, Cambridge CB2 2QQ


**Herpes simplex infections in atopic eczema**

SIR.—Patients with atopic eczema have an increased susceptibility to cutaneous viral infections, including herpes simplex, common cold, warts, vaccinia, and molluscum contagiosum. This is thought to be due partly to a mild but definite depression of T cell function.1 I was struck, however, by the apparent high incidence of the herpes simplex infection in children admitted to the Birmingham Children’s Hospital with an acute exacerbation of atopic eczema. To test my observations, I did a retrospective study of patients, common cold, warts those admitted over a period of two years and a prospective study over a period of one year. Swabs were taken if herpes simplex was clinically suspected—that is, there were vesicles or pustules in a child with atopic eczema. The presence of the herpes simplex virus was tested by indirect immunofluorescence and cytopathic changes on tissue culture.

During two year period, 10 out of 119 children were confirmed to have a herpes simplex skin infection. The prospective study, over a period of one year, showed eight out of 74 children with atopic eczema to have a confirmed herpes simplex skin swab. Thus during the combined three year period, the incidence of the virus was approximately 10%. Two children had one recurrence and one child had two recurrences.

All children confirmed to have a herpes simplex skin infection improved after seven to 10 days even though two, initially, had developed severe systemic upset. They were all treated with a five day course of oral acyclovir. Herpes simplex was confirmed in all children who were clinically suspected of having the virus, reflecting the ease of diagnosis and of culture of the virus. The incidence of about 10% of herpes simplex infection in acutely exacerbated atopic eczema was also found by David and Longson.2 This incidence may have been an underestimate as swabs were only taken on clinical suspicion that the virus was present. There may have been similar underestimations in our study. When infected eczema fails to respond to antibiotics within two days this is thought to suggest a herpes simplex infection.2 It would be interesting to determine the incidence of the herpes simplex virus in acute eczema when it is not clinically obvious.

This study confirms my observation of the high incidence of herpes simplex in atopic eczema. It should therefore be considered in an acute exacerbation of atopic eczema as it can cause considerable associated systemic disease.

B J LIDDLE
The General Hospital, Steelhouse Lane, Birmingham B4 6NH

1 Campenot FJ, Winkelmann RK, Jordan JT. T and B lymphocyte contact and atopic dermatitis, *Arch Dermatol* 1976;112:1095-100.


**Self management plans for asthma**

SIR.—Comics and booklets, training courses for patients, asthma nurses—do they help to reduce morbidity in asthma? The evidence is at worst negative and at best contradictory. A consensus is emerging that self management is key to good control and that a clearly written set of instructions—a self management plan—is the means to achieve this goal.

The article by Fletcher et al suggests that clear advice might have helped to prevent some deaths from asthma.1 Two recent articles from Thorax come to similar conclusions.

Sibbald concluded that psychological factors were not major determinants of the responses of her adult asthmatic subjects to two hypothetical attacks of asthma.2 Simple messages, teaching patients how to cope rather than trying to improve their knowledge of disease, would be most likely to reduce morbidity. A self management scheme of this type was assessed in an earlier study by Beak and colleagues.3 A written plan and a peak flow meter were provided for each of the subjects. Patients improved over a seven month period, suggesting that the plan was successful. A controlled study, with an assessment of the (non-standard) advice given and an analysis of the important features which were responsible for improved control, will be essential sequels to this study.

Of immediate practical help, the National Asthma Campaign has recently introduced two children’s asthma cards, based largely on a similar design used successfully at Hammersmith Hospital for over 10 years.4 One card is for personal use by patients or parents. The other is designed for teachers. There are sections for regular treatment, relief treatment, and emergency management. Brief guidelines are printed for the emergency doctor and for the parents or school teachers. The cards are also available to schools. The National Asthma Campaign, 300 Upper Street, London N1 2XX. I urge you to use them.

M SILVERMAN
Royal Postgraduate Medical School, Hammersmith Hospital, London W12 0HS


**Effect of fever on recurrence rate of febrile convulsions**

SIR.—The paper by Drs El-Radhi and Banajeh may be criticised on the grounds that they have combined data from retrospective and prospective studies for joint analysis.1 Even if their results were to be accepted at face value, I suspect that they have drawn the wrong conclusion from their data. Rather than suggesting that the height of the initial fever provides stimulation of non-specific immunity, thereby reducing the chance of further infections (are we therefore misguided in trying to lower fever?), it is surely more reasonable to interpret their data by assuming that there is a natural variation in the temperature threshold required for convolution. Any individual may convulse if the temperature rises high enough, as in heat stroke, and as the incidence of febrile convolution decreases with age, cerebral maturation appears to be associated with increase in temperature threshold required for convolution. Their groups are clearly self selecting: those infants convulsing with temperatures below 39°C have a low temperature threshold and would be expected to have more attacks, as more infections cause pyrexias of 38–39°C than 40–41°C. Those requiring temperatures above 40°C will have less, both because a high pyrexia is less common, and because their convolution threshold will increase naturally with age to levels above those caused by infectious illness.

Perhaps we should be directing our attention to those infants who present with convolution associated with low grade fever. Simple methods of fever control are less likely to prevent a pyrexia of 38-5°C than one of 40–41°C, and it may be important to consider early introduction of anticonvulsant treatment in this group. This could be withdrawn after a relatively short period of six months to one year, as the infant’s convolution threshold may well have risen to levels where fever control alone is adequate.

S MURCH
Department of Child Health, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE

Monitoring treatment in congenital adrenal hyperplasia.

I A Hughes

Arch Dis Child 1990 65: 333
doi: 10.1136/adc.65.3.333

Updated information and services can be found at:
http://adc.bmj.com/content/65/3/333.1.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/